Pharmacologic activation of p53 by small-molecule MDM2 antagonists.
Pharmacologic activation of p53 by small-molecule MDM2 antagonists.
复制标题
DOI:
10.2174/138161211795222603
复制
发表时间:
2011
影响因子:
3.1
通讯作者:
Maki CG
中科院分区:
文献类型:
--
作者:
Shen H;Maki CG
Restoring p53 activity by inhibiting the interaction between p53 and MDM2 represents an attractive approach for cancer therapy. To this end, a number of small-molecule p53-MDM2 binding inhibitors have been developed during the past several years. Nutlin-3 is a potent and selective small-molecule MDM2 antagonist that has shown considerable promise in pre-clinical studies. This review will highlight recent advances in the development of small-molecule MDM2 antagonists as potential cancer therapeutics, with special emphasis on Nutlin-3.
登录
查看更多内容
影响因子:
7.3
作者:
Ahmed, Ashour Ahmed;Etemadmoghadam, Dariush;Temple, Jillian;Lynch, Andy G.;Riad, Mohamed;Sharma, Raghwa;Stewart, Colin;Fereday, Sian;Caldas, Carlos;DeFazio, Anna;Bowtell, David;Brenton, James D.
通讯作者:
Brenton, James D.
影响因子:
8.8
作者:
通讯作者:
--
影响因子:
4.8
作者:
Hu, Baoli;Gilkes, Daniele M.;Chen, Jiandong
通讯作者:
Chen, Jiandong
影响因子:
5.2
作者:
Huang, Baoying;Deo, Dayanand;Vassilev, Lyubomir T.
通讯作者:
Vassilev, Lyubomir T.
影响因子:
8
作者:
Bálint, E;Bates, S;Vousden, KH
通讯作者:
Vousden, KH